Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients.

Conclusion: Rituximab is safe and effective in childhood/juvenile patients with AIBDs. Furthermore, RTX can be used as first-line treatment in pediatric patients with pemphigus. PMID: 32589481 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32589481?dopt=Abstract

Source: Journal of Dermatological Treatment - June 28, 2020 Category: Dermatology Tags: J Dermatolog Treat Source Type: research